Search Results

1 - 10 of 19 items :

  • "acute promyelocytic leukemia" x
Clear All

References 1. Horna P., Zhang L., Sotomayor E.M., Lancet J.E., Moscinski L.C. Diagnostic Immunophenotype Of Acute Promyelocytic Leukemia Before And Early During Therapy With All-Trans Retinoic Acid. Am J Clin Pathol. 2014; 142(4):546-52. 2. Carella A.M., Antonucci G., Conte M., Di Pumpo M., Antonucci E., Ponziano E. A Case Of Ischemic Stroke In Acute Promyelocytic Leukemia At Initial Presentation. Relevance Of All-Trans Retinoic Acid Treatment. Cardiovasc Hematol Disord Drug Targets. 2010; 10(1):1-6. 3. Falanga A., Barbui T. Coagulopathy Of Acute Promyelocytic

References 1. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990; 8 (11): 1913-21. 2. Warrell RP Jr, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993; 329 (3): 177-89. http://dx.doi.org/10.1056/NEJM199307153290307 3. Davey FR, Davis RB, MacCallum JM, et al. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol 1989; 30 (4): 221-7. http://dx.doi.org/10.1002/ajh.2830300406 4. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15

Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol 2016 Jul;1-14. 18. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology 2015 Oct;16(13): 1295-305. DOI: 10.1016/S1470-2045(15)00193-X 19. Imagawa J, Harada Y, Shimomura T, Tanaka H, Okikawa Y, Hyodo H, et al. Clinical and genetic features of therapy-related myeloid neoplasms

treatment of thyroid cancer with radioiodine. Br J Radiol 59 (697): 45-51. Fallahi B, Adabi K, Majidi M, Fard-Esfahani A, Heshmat R, Larijani B, Haghpanah V. (2011). Incidence of second primary malignancies during a longterm surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clin Nucl Med 36 (4): 277-282. Fenech M. (2000). The in vitro micronucleus technique. Mutat Res 455 (1-2): 81-95. Grudeva-Popova J, Yaneva M, Zisov K, Ananoshtev N. (2007). Therapy-related acute promyelocytic leukemia after treatment with

leukemia. Arch Med Res. 1997; 28(2): 209-214. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood. 1996; 87(1): 308-313. Al Bahar S, Pandita R, Bavishi K, Kreze O, Nath S. Chromosome aberrations in de novo acute myeloid leukemia patients in Kuwait. Neoplasma. 2004; 51(3): 223-227. Udayakumar AM, Pathare AV, Al-Kindi S, Khan H, Rehmen JU, Zia F, Al-Ghazaly A, Nusrut N, Khan MI, Wali YA, Al-Lamki Z, Dennison D, Raeburn JA. Cytogenetic, morphological, and

Diagnosis. 2nd revised edition 2004. Munich, 106-9. 10. Glaubach T, Robinson L.J, Corey S.J Pediatric Myelodysplastic Syndromes: They Do Exist! J Pediatr Hematol Oncol. 2014;36:1-7. DOI: 10.1097/MPH.0000000000000046 11. Elghetany TM. Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series. Arch Pathol Lab Med. 2007;131:1110-6. 12. Cîrstea M, Coliță A, Ionescu B, Ghiaur A, Vasilescu D, et al. Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic

leukemia. Global J Biochem 2012; 3(8): 1-16. 89. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-18. 90. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-8. 91. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of alltrans retinoic acid (ATRA) followed by

-7836.2007.02379.x. 39. Yu F, Du Y, Han B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol. 2016;103:649-654. doi: 10.1007/s12185-016-1995-1. 40. Shin HS, Kang TS. A Case of Late Stent Thrombosis Following Platelet Transfusion in a Patient With Aplastic Anemia. Korean Circ J. 2012;42:54–57. doi: 10.4070/kcj.2012.42.1.54. 41. Altwegg SC, Altwegg LA, Maier W. Intracoronary thrombus with tissue factor expression heralding acute promyelocytic leukaemia. Eur Heart J. 2007;28:2731. doi

factors, and effect on survival. Blood. 2009 113(17):3911-17. DOI: 10.1182/ blood-2008-08-175745 7. Qian X, Wen-Jun L. Platelet Changes in Acute Leukemia. Cell Biochem Biophys. 2013 Dec;67(3):1473-9. DOI: 10.1007/s12013-013-9648-y 8. Stein E, McMahon B, Kwaan H, Altman JK, Frankfurt O, Tallman MS. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol. 2009 Mar;22(1):153-63. DOI: 10.1016/j. beha.2008.12.007 9. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis

Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. DOI: 10.1182/blood-2016-03-643544 4. Coriu D, Jardan D, Jardan C, Tălmaci R, Dragomir M, Coliţă A. A new assay to identify recurrent mutations in acute myeloid leukemia using next-generation sequencing. Rev Romana Med Lab. 2014;22(1):93-9. DOI: 10.2478/rrlm-2014-0003 5. Cîrstea M, Coliță A, Ionescu B, Ghiaur A, Vasilescu D, Dobrea C, et al. Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: case report and literature